Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Exxon Mobil Corporation

Announced: October 11, 2023
Value: $64.5 billion
Status: Pending

Financial advisor to ExxonMobil on its acquisition of Pioneer Natural Resources

Seagen Inc.

Announced: March 13, 2023
Value: $44.5 billion
Status: Pending

Exclusive financial advisor to Seagen on its sale to Pfizer

FIS

Announced: July 6, 2023
Value: Up to $18.5 billion
Status: Pending

Financial advisor to FIS on its sale of a majority stake in its Worldpay business to GTCR

Newmont Goldcorp Corporation

Announced: February 6, 2023
Value: $17 billion
Status: Closed

Financial advisor to Newmont on its proposal for an acquisition of Newcrest Mining Limited

Prometheus Biosciences

Announced: April 16, 2023
Value: $10.8 billion
Status: Closed

Financial advisor to Prometheus on its sale to Merck

Oak Street Health, Inc.

Announced: February 8, 2023
Value: $10.6 billion
Status: Closed

Sole financial advisor to Oak Street Health on its sale to CVS Health

Emerson Electric Co.

Announced: April 12, 2023
Value: $8.6 billion
Status: Pending

Financial advisor to Emerson on its acquisition of NI

Syneos Health, Inc

Announced: May 10, 2023
Value: $7.1 billion
Status: Pending

Lead financial advisor to Syneos Health on its sale to a private investment consortium comprised of Elliott Investment Management, Patient Square Capital and Veritas Capital

Iveric Bio

Announced: April 30, 2023
Value: $5.9 billion
Status: Closed

Financial advisor to Iveric on its sale to Astellas

Mirati Therapeutics, Inc.

Announced: October 8, 2023
Value: $5.8 billion
Status: Pending

Exclusive financial advisor to Mirati on its sale to Bristol-Myers Squibb

Diversey Holdings, Ltd.

Announced: March 8, 2023
Value: $4.6 billion
Status: Closed

Financial advisor to Diversey on its sale to Solenis

Thales SA

Announced: July 25, 2023
Value: $3.6 billion
Status: Pending

Financial advisor to Thales on its acquisition of Imperva from Thoma Bravo

Chinook Therapeutics, Inc.

Announced: June 12, 2023
Value: Up to $3.5 billion
Status: Closed

Exclusive financial advisor to Chinook on its sale to Novartis

Carmot Therapeutics, Inc.

Announced: December 3, 2023
Value: Up to $3.1 billion
Status: Pending

Lead financial advisor to Carmot on its sale to Roche

Trimble Inc.

Announced: September 28, 2023
Value: $3 billion
Status: Pending

Exclusive financial advisor to Trimble on its joint venture with AGCO

Provention Bio

Announced: March 13, 2023
Value: $2.9 billion
Status: Closed

Financial advisor to Provention on its sale to Sanofi

Sovos Brands Holdings, Inc

Announced: August 7, 2023
Value: $2.7 billion
Status: Pending

Financial advisor to Sovos Brands on its sale to Campbell

L'Oréal S.A.

Announced: April 3, 2023
Value: $2.5 billion
Status: Closed

Exclusive financial advisor to L'Oréal on its acquisition of Aesop from Natura &Co

DICE Therapeutics, Inc.

Announced: June 20, 2023
Value: $2.4 billion
Status: Closed

Exclusive financial advisor to DICE on its sale to Eli Lilly

Rover Group, Inc.

Announced: November 29, 2023
Value: $2.3 billion
Status: Pending

Financial advisor to Rover on its sale to Blackstone

Kering SA

Announced: July 27, 2023
Value: €1.7 billion
Status: Pending

Exclusive financial advisor to Kering on its acquisition of a significant share of Valentino from Mayhoola

OneOncology, Inc.

Announced: April 20, 2023
Value: $2.1 billion
Status: Closed

Exclusive financial advisor to OneOncology and General Atlantic on OneOncology's sale to TPG and AmerisourceBergen

BELLUS Health Inc.

Announced: April 18, 2023
Value: $2 billion
Status: Closed

Exclusive financial advisor to BELLUS on its acquisition by GSK plc

C&S

Announced: September 8, 2023
Value: $1.9 billion
Status: Pending

Exclusive financial advisor to C&S on its acquisition of 413 stores, eight distribution centers and two offices that have become available from the Kroger and Albertsons merger

CinCor Pharma, Inc.

Announced: January 9, 2023
Value: Up to $1.8 billion
Status: Closed

Exclusive financial advisor to CinCor Pharma on its sale to AstraZeneca

The Restaurant Group plc

Announced: October 12, 2023
Value: £1.1 billion
Status: Pending

Financial advisor to TRG on Apollo's offer to purchase TRG

CTI BioPharma Corp.

Announced: May 10, 2023
Value: $1.7 billion
Status: Closed

Financial advisor to CTI on its sale to Sobi

Chiesi Farmaceutici S.p.A.

Announced: January 8, 2023
Value: Up to $1.5 billion
Status: Closed

Exclusive financial advisor to Chiesi Farmaceutici on its acquisition of Amryt Pharma Plc

POINT Biopharma Global Inc.

Announced: October 3, 2023
Value: $1.4 billion
Status: Pending

Exclusive financial advisor to POINT Biopharma on its sale to Eli Lilly

VectivBio AG

Announced: May 22, 2023
Value: $1.2 billion
Status: Closed

Lead financial advisor to VectivBio on its sale to Ironwood

Trinseo PLC

Announced: September 8, 2023
Value: $1.077 billion
Status: Closed

Exclusive financial advisor to Trinseo on its secured term loan financing from Angelo Gordon, Oaktree and Apollo

Inversago Pharma Inc.

Announced: August 10, 2023
Value: Up to $1.075 billion
Status: Closed

Exclusive financial advisor to Inversago on its sale to Novo Nordisk

Daou Vineyards, LLC

Announced: October 30, 2023
Value: Up to $1 billion
Status: Pending

Exclusive financial advisor to DAOU on its sale to Treasury Wine Estates

Standard BioTools Inc.

Announced: October 4, 2023
Value: $1 billion
Status: Pending

Sole financial advisor to Standard BioTools on its all-stock merger with SomaLogic

Intercept Pharmaceuticals

Announced: September 26, 2023
Value: $1 billion
Status: Pending

Financial advisor to Intercept on its sale to Alfasigma

Pfizer

Announced: July 28, 2023
Value: Up to $1 billion
Status: Pending

Exclusive financial advisor to Pfizer on the sale of a portfolio of preclinical gene therapy programs and enabling technologies to AstraZeneca Rare Disease

JBT Corporation

Announced: May 30, 2023
Value: $800 million
Status: Closed

Financial advisor to JBT on the sale of its AeroTech business to Oshkosh

Nautic Partners, LLC

Announced: August 7, 2023
Value: $650 million
Status: Pending

Financial advisor to Nautic Partners and its portfolio company ExactCare Pharmacy, on the acquisition of Tabula Rasa

Teleflex

Announced: July 26, 2023
Value: Up to $650 million
Status: Pending

Exclusive financial advisor to Teleflex on its acquisition of Palette Life Sciences

Forge Biologics

Announced: November 13, 2023
Value: $620 million
Status: Pending

Exclusive financial advisor to Forge on its sale to Ajinomoto

Diageo plc

Announced: January 17, 2023
Value: Up to €437.5 million
Status: Closed

Exclusive financial advisor to Diageo on its acquisition of Don Papa Rum

Thomson Reuters

Announced: April 4, 2023
Value: $500 million
Status: Closed

Exclusive financial advisor to Thomson Reuters on the sale of a majority ownership stake in its Elite business to TPG, establishing Elite as an independent legal tech company

Johnson Controls Inc.

Announced: July 17, 2023
Value: $455 million
Status: Pending

Exclusive financial advisor to Johnson Controls on its acquisition of FM:Systems

Li-Cycle Holdings Corp.

Announced: March 27, 2023
Value: $375 million
Status: Pending

Exclusive financial advisor to Li-Cycle on its conditional commitment for a loan from the U.S. Department of Energy

LianBio

Announced: October 24, 2023
Value: $350 million
Status: Closed

Exclusive financial advisor to LianBio on the sale of its exclusive rights to to develop and commercialize mavacamten in Greater China, Singapore and Thailand to Bristol Myers Squibb

International Flavors & Fragrances Inc.

Announced: February 16, 2023
Value: $220 million
Status: Closed

Exclusive financial advisor to IFF on the sale of its Flavor Specialty Ingredients business to Exponent

Decibel

Announced: August 9, 2023
Value: Up to $213 million
Status: Closed

Exclusive financial advisor to Decibel on its sale to Regeneron Pharmaceuticals

Designer Brands Inc.

Announced: June 8, 2023
Value: $100 million
Status: Closed

Exclusive financial advisor to Designer Brands on its Dutch Auction tender offer and new term loan financing

Wiley

Announced: November 14, 2023

Exclusive financial advisor to Wiley on the divestiture of its Wiley University Services business to Academic Partnerships

Hobbs & Associates, Inc.

Announced: October 9, 2023
Status: Closed

Exclusive financial advisor to Hobbs receiving a growth investment from Madison Dearborn Partners, LLC

PTC Inc

Announced: October 4, 2023
Status: Closed

Exclusive financial advisor to PTC on its acquisition of pure-systems

Learfield Sports, LLC

Announced: September 13, 2023
Status: Closed

Exclusive investment banker to the ad-hoc group of secured creditors on the completion of an out-of-court recapitalization and comprehensive deleveraging transaction for Learfield

National CineMedia, Inc.

Announced: August 8, 2023
Status: Closed

Exclusive financial advisor to the ad-hoc group of secured creditors on National CineMedia's completion of its financial restructuring and emergence from chapter 11

Kohlberg & Company, L.L.C.

Announced: August 7, 2023
Status: Pending

Exclusive financial advisor to Kohlberg & Company on its acquisition of Worldwide Clinical Trials

Kering SA

Announced: June 26, 2023
Status: Pending

Financial advisor to Kering on its acquisition of Creed

Santhera Pharmaceuticals

Announced: June 20, 2023
Status: Closed

Financial advisor to Santhera on its exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals

SVB Financial Group

Announced: June 18, 2023
Status: Pending

Financial advisor to SVB Financial Group on the sale of SVB Securities to the Management Team Group led by Jeff Leerink and backed by Baupost

Bansk Group LLC

Announced: June 5, 2023
Status: Closed

Financial advisor to Bansk Group and its portfolio company Arcadia, on Arcadia's acquisition of Avrio Health

CarePathRx

Announced: June 1, 2023
Status: Closed

Lead financial advisor to CarepathRx on the announcement of a two-step sale of Carepath Health System Solutions to Cigna

Riverbed Technology, Inc.

Announced: May 30, 2023
Status: Closed

Financial advisor to Riverbed on its sale to Vector Capital

Gates Industrial Corporation plc

Announced: May 17, 2023
Status: Closed

Co-Manager on Gates’ secondary offering of shares held by Blackstone affiliates

Revlon, Inc.

Announced: April 5, 2023
Status: Closed

Exclusive investment banker to the BrandCo Ad-Hoc Group to Revlon on the Company's Plan of Reorganization

Credit Suisse Group AG

Announced: March 19, 2023
Status: Pending

Sole financial advisor to Credit Suisse on its merger with UBS

KHAITE

Announced: March 10, 2023
Status: Closed

Financial advisor to KHAITE on its investment from Stripes

Redx Pharma Plc

Announced: February 23, 2023
Status: Withdrawn

Exclusive financial advisor to Redx on its merger with Jounce Therapeutics

Red Collar Pet Foods, Inc.

Announced: February 7, 2023
Status: Closed

Exclusive financial advisor to Red Collar on its sale of a treats factory to Nestlé Purina PetCare

Bacardi Limited

Announced: February 3, 2023
Status: Closed

Exclusive financial advisor to Bacardi on its acquisition of a majority interest in D’USSÉ

International Flavors & Fragrances Inc.

Announced: February 2, 2023
Status: Closed

Exclusive financial advisor to IFF on recent changes to its Board of Directors

Serta Simmons Bedding, LLC

Announced: January 24, 2023
Status: Pending

Financial advisor to the ad hoc group of priority term loan lenders on Serta Simmons Bedding's chapter 11 filing and Restructuring Support Agreement

Albireo Pharma, Inc.

Announced: January 9, 2023
Status: Closed

Exclusive financial advisor to Albireo on its sale to Ipsen

Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.